Eptinezumab-jjmr (Vyepti) — CPB 0970 | AETNA Coverage Update

Aetna modified CPB 0970 covering eptinezumab-jjmr (Vyepti) for migraine prevention, effective December 10, 2025. Here's what billing teams need to know before submitting claims.

Aetna, a CVS Health company, updated its Vyepti coverage policy under CPB 0970 Aetna system. The policy governs HCPCS code J3032 (eptinezumab-jjmr, 1 mg) billed alongside CPT codes 96365 and +96366 for IV infusion administration. The change tightens the reauthorization standard — continuation of therapy now requires documented reduction in migraine days per month from baseline, not just ongoing use.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Eptinezumab-jjmr (Vyepti) — CPB 0970
Policy Code	CPB 0970
Change Type	Modified
Effective Date	December 10, 2025
Impact Level	High
Specialties Affected	Neurology, Headache Medicine, Infusion Centers, Specialty Pharmacy
Key Action	Confirm baseline migraine day documentation exists before submitting reauthorization for any patient past the 3-month mark

---

Aetna Vyepti Coverage Criteria and Medical Necessity Requirements 2025

The Aetna Vyepti coverage policy under CPB 0970 splits approval into two phases: initial approval and continuation of therapy. Each has distinct medical necessity requirements. Mixing them up is the fastest way to a claim denial.

Initial Approval

For initial authorization, Aetna considers J3032 medically necessary for adult members getting Vyepti for migraine prevention — as long as the member has not yet received three months of treatment with eptinezumab-jjmr. That's the only clinical threshold stated for initial approval. There's no step therapy requirement listed in this policy, no required failure of oral preventives, and no minimum migraine frequency threshold.

That's a relatively clean standard by CGRP standards. But don't let that simplicity lull you into skipping precertification.

Precertification is required. Full stop. All Aetna participating providers and members on applicable plan designs must get prior authorization before infusion. Call (866) 752-7021 or fax your Statement of Medical Necessity form to (888) 267-3277.

Continuation of Therapy

This is where the real billing exposure sits. For reauthorization — any patient who has received at least three months of eptinezumab-jjmr — Aetna requires two things:

#	Covered Indication Copy
1	The member has received at least three months of Vyepti
2	The member has had a reduction in migraine days per month from baseline

The second criterion is the critical one. Aetna isn't asking whether the drug helped. It's asking for a documented, measurable reduction from a recorded baseline. If your clinical team never captured a baseline migraine day count before treatment started, you cannot demonstrate response — and Aetna will deny the reauthorization.

This is not a new concept in CGRP policy, but it's a concrete articulation of what many payers have been moving toward. If your neurology practice hasn't built baseline migraine diary documentation into your Vyepti intake workflow, do it now.

Site of Care

Vyepti is an IV infusion. Aetna's Site of Care Utilization Management Policy applies here. That means Aetna reviews where the infusion happens, not just whether it's covered. Infusion centers, hospital outpatient settings, and home infusion each carry different reimbursement implications. Confirm your infusion site is consistent with Aetna's site-of-care policy before scheduling — or you risk a site-of-service denial even when the drug itself is authorized.

Medicare Note

This policy covers commercial plans only. For Medicare patients receiving Vyepti, CPB 0970 does not apply. Refer to Aetna's separate Medicare Part B criteria. Don't apply commercial billing guidelines to a Medicare claim for J3032.

---

Aetna Vyepti Exclusions and Non-Covered Indications

Aetna considers all uses of eptinezumab-jjmr outside migraine prevention to be experimental, investigational, or unproven. The policy is explicit: there's no other covered indication.

Cluster headaches, tension-type headaches, post-traumatic headache — none of these are covered under CPB 0970. If a provider submits J3032 with an ICD-10 outside the G43.001–G43.E19 migraine range, expect a denial. The diagnosis code has to land squarely in the migraine block.

Also watch out for the CGRP self-injectable crossover. Aimovig, Ajovy, and Emgality are a different drug class — CGRP receptor antagonist injectables, not IV infusions — and they route through the pharmacy benefit, not the medical benefit. HCPCS J3031 (fremanezumab-vfrm, 1 mg) is listed in this policy but routes to the pharmacy benefit. Don't bill J3031 under the medical benefit expecting it to fall under CPB 0970 authorization.

---

Coverage Indications at a Glance

---

Aetna Vyepti Billing Guidelines and Action Items 2025

The effective date of December 10, 2025 means any claim for J3032 submitted on or after that date falls under these updated criteria. Here's what to do now.

1. Audit your active Vyepti patients for baseline documentation.

Pull every patient currently on Vyepti. For anyone approaching or past the three-month mark, confirm that your clinical team recorded a baseline migraine days-per-month count before treatment started. If that number isn't in the chart, contact the prescribing neurologist to reconstruct it from intake notes or migraine diary records before you submit reauthorization. A reauth without a baseline comparison is a denial waiting to happen.

2. Build baseline capture into your Vyepti intake workflow.

For every new Vyepti patient, the intake process must include a documented migraine frequency baseline — days per month, severity, and duration. This is the data you'll need at the three-month reauthorization. Set it up as a required field in your EHR template now, before the next new start.

3. Confirm precertification before every infusion.

Eptinezumab-jjmr billing under J3032 requires prior authorization without exception. Call (866) 752-7021 or fax to (888) 267-3277. Keep your authorization number in the claim file. Don't schedule the infusion until you have the auth in hand.

4. Verify site-of-care authorization separately.

Aetna's Site of Care policy applies to Vyepti infusions. The drug auth and the site-of-service approval are separate considerations. Confirm your infusion setting — outpatient clinic, infusion center, or home infusion — is consistent with Aetna's site-of-care requirements for specialty drug infusions. If you're unsure, check Aetna's Utilization Management Policy on Site of Care for Specialty Drug Infusions directly.

5. Code the infusion correctly with 96365 and +96366.

J3032 covers the drug itself at 1 mg per unit. The administration goes on 96365 for the initial infusion hour and +96366 for each additional hour. Both codes must appear on the claim. Missing the add-on code leaves reimbursement on the table. Confirm your charge capture includes both CPT codes every time J3032 is billed.

6. Use ICD-10 codes from within G43.001–G43.E19 only.

Vyepti coverage under CPB 0970 is restricted to migraine diagnoses. The full covered range runs from G43.001 through G43.E19. Any diagnosis code outside that range will produce a medical necessity denial. Verify your superbill and charge capture default to a valid migraine ICD-10 — not a headache NOS code.

7. Separate commercial and Medicare workflows.

CPB 0970 applies to commercial plans only. If you're billing Aetna Medicare Advantage for J3032, the criteria are different — use the Medicare Part B criteria Aetna publishes separately. Applying the commercial coverage policy to a Medicare claim is a common error with real downstream consequences. If your team handles both populations, flag the distinction in your Aetna-specific billing guidelines now.

If you're unsure how this policy applies to your specific patient mix or contract terms, loop in your compliance officer before December 10, 2025.

---

CPT, HCPCS, and ICD-10 Codes for Eptinezumab-jjmr (Vyepti) Under CPB 0970

Covered CPT Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
96365	CPT	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to one hour
+96366	CPT (add-on)	Intravenous infusion, each additional hour (list separately in addition to code for primary procedure)

Covered HCPCS Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
J3032	HCPCS	Injection, eptinezumab-jjmr, 1 mg

Other HCPCS Codes Referenced (Pharmacy Benefit — Not Medical Benefit Under CPB 0970)

Code	Type	Description	Notes Copy
J3031	HCPCS	Injection, fremanezumab-vfrm, 1 mg	Routes to pharmacy benefit; CGRP injectable — not covered under CPB 0970 medical benefit

Key ICD-10-CM Diagnosis Codes

Code Range	Description Copy
G43.001 – G43.E19	Migraine (full range of migraine subtypes)

Confirm your billing system maps to a valid code within this range. Codes outside G43.001–G43.E19 will not satisfy the medical necessity requirement under CPB 0970.

---